There was a mistake in Figure 3C as published. The GAPDH western blot image in Figure 3C was unintentionally incorrectly used. The corrected Figure 3C appears below.
Figure 3
Fingolimod increased Bcl-2/Bax ratio but did not reduce the number of TUNEL + cells at 24 h after tMCAO. (A), Micrographs of TUNEL staining in the peri-infarct region of DM + MCAO and DM + MCAO + F groups. Scale bar, 50 μm. Left panel showing the sketch of the brain section, boxes in it illustrating fields we are sampling in. (B), Bar graph is the quantification of the number of TUNEL+ cells in DM + MCAO and DM + MCAO + F groups (n = 3/group). (C), Western blot results of apoptotic factors Bcl-2 and Bax. (D), Bar graph is the quantification of Bcl-2/Bax ratio based on Western blot data [n (Sham) = 3, n (DM + MCAO) = 3, n (DM + MCAO + F) = 6]. MW, molecular weight. Data are presented as mean ± SEM, *p < 0.05, **p < 0.01.
In the published article, there was an error in citing data within the Results section.
A correction has been made to Results, Acute Treatment with Fingolimod Failed to Improve Endpoint Outcomes at 24 h After tMCAO in Diabetic Mice, Paragraph 2. This sentence previously stated:
“No significant difference in neurological score (DM + MCAO vs. DM + MCAO + F, 12.40 ±3.29 vs. 15.42 ±4.12) (Figure 1E) or brain infarction volume (DM + MCAO vs. DM + MCAO + F, 62.81 ±3.15 mm3 vs. 71.22 ±3.98 mm3) (Figures 1F–G) was observed.”
The corrected sentence appears below:
“No significant difference in neurological score (DM + MCAO vs. DM + MCAO + F, 12.40 ±3.29 vs. 15.42 ± 4.12) (Figure 1E) or brain infarction volume (DM + MCAO vs. DM + MCAO + F, 40.7 ± 8.90 mm3 vs. 34.4 ± 6.97 mm3) (Figures 1F–G) was observed.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
diabetic stroke, diabetes mellitus, fingolimod, edema, inflammation
Citation
Li W, He T, Jiang L, Shi R, Song Y, Mamtilahun M, Ma Y, Zhang Z, Tang Y, Yang G-Y and Wang Y (2025) Correction: Fingolimod inhibits inflammation but exacerbates brain edema in the acute phases of cerebral ischemia in diabetic mice. Front. Neurosci. 19:1639244. doi: 10.3389/fnins.2025.1639244
Received
01 June 2025
Accepted
02 June 2025
Published
19 June 2025
Volume
19 - 2025
Edited and reviewed by
Mark P. Burns, Georgetown University, United States
Updates
Copyright
© 2025 Li, He, Jiang, Shi, Song, Mamtilahun, Ma, Zhang, Tang, Yang and Wang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Guo-Yuan Yang gyyang0626@163.comYongting Wang ytwang@sjtu.edu.cn; yongting.wang@gmail.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.